The scientific community has collected a great amount of a genomic information that relates to cancer biology. Sequencing the cancer genome was first completed in 2007. Since then, a lot of research is concerned with finding missing information and data to fill in the gaps of understanding. The main goal has been to focus on what causes cancer as well as tumor suppressors and oncogenes. The latest biological information and research can help us create therapy and strategies for care that were not possible before. Much of this can be done to prevent cancer and to limit its ability to spread. More data means that the process of managing cancer cells will be possible with the greater accuracy and precision. For the past four decades, billions have been invested in understanding what drives cancer. The government is responsible for more than 90 billion dollars in the past 25 years alone.
Cancer research about biology requires extensive analysis that is completed with the help of hundreds of institutions around the world. Hospitals and research centers have been trying to understand the way that genetic information plays into preventing and treating the disease by collecting the most specialized information. Biomarkers regarding specific kinds of cancers are amongst some of the discoveries that have taken the field by storm and allow for greater treatment methods and systems.
Because of the large-scale implications of understanding cancer biology, it is important that the scientific community continues to find and develop technology that includes genetic information. This is because cancer biology and other genetic research will contribute to the future of treatment and prevention options.
One way that research will continue in this area is by integrating tools for oncologist that will combine research and clinical outcomes into one system. This would allow specific data to be gathered such as phenotypic, molecular and therapeutic aspects.Tempus, co-founded by Eric Lefkofsky is interested in providing the technology that will integrate clinical and research objectives to lead this type of research.
Doing so would allow for the industry to gather enough data to inform treatment development and design. This would help organize the vast amount of information that is gathered through a large-scale system like this, while providing an “operating system”to navigate future cancer biology research. Eric Lefkofksy explains that it will be increasingly important for physicians to have the right tools to integrate patient data and findings with existing hospital infrastructure. This will provide a seamless method of investigative research in cancer biology.